Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Exposure Risk Intensifying For Generic Drug Makers

Executive Summary

Business fundamentals took a back seat to opioid litigation in the second quarter for generic drug makers, including Teva, Mallinckrodt and Endo Pharmaceuticals.

You may also be interested in...



Sandoz Recalls Antacid In Another Generics Firestorm

The Novartis unit moved to recall all lots of ranitidine capsules in the US due to confirmed contamination with NDMA.

Purdue Pharma: From Blockbuster Success To Bankrupt Villain

Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry. 

Opioid Litigation Pushes American Pain Society Into Bankruptcy

Labeled by plaintiffs as a 'front group' for opioid makers, the organization was pulled into the multidistrict litigation in Ohio and filed for Chapter 7 bankruptcy in June. It ceased operations in July.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125681

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel